Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
Lucie Raskin, PhD student at University of Namur, shared on LinkedIn:
”Glad to have presented at NTHC 2026 (Namur Thrombosis and Hemostasis Center)!
I had the opportunity to share our work on a Network Meta-Analysis (NMA) assessing the risk of venous thromboembolism (VTE) associated with hormonal contraceptives (HCs).
This analysis allows us, within a single model, to compare the full range of HCs and to classify VTE risk according to the type of contraceptive.
By integrating all available evidence, this work provides a comprehensive overview that complements biological data and real-world pharmacovigilance findings.
Altogether, the evidence consistently suggests that natural estrogens may represent a safer option compared to EE-based COCs with respect to VTE risk.
I would like to thank my supervisors Jonathan Douxfils and Charlotte Beaudart, as well as the Research Unit in Clinical Pharmacology and Toxicology (URPC) team for their support.”
Stay updated with Hemostasis Today.
-
May 26, 2026, 14:14Fredrick Chalinga: The Reality of Massive Transfusion in Emergency Medicine
-
May 26, 2026, 14:09Tareq Abadl: Slide Method vs Tube Method in Blood Grouping
-
May 26, 2026, 14:07Fernanda Flygare: HI-PEITHO Trial Highlights Benefits of EKOS-Assisted Catheter-Directed Thrombolysis in PE
-
May 26, 2026, 14:05Arvind Kumar: The Science Behind Clot Retraction in Hemostasis
-
May 26, 2026, 14:01Maria Fredin Grupper: WHA79 Adopts Landmark WHO Resolution on Stroke
-
May 26, 2026, 13:54Awareness Enables Diagnosis, Diagnosis Enables Care, and Care Changes Lives – EHC
-
May 26, 2026, 13:47Masoabi Sefojane: Reflections on Bleeding Disorder Care in LMICs From the WFH Africa Regional Workshop
-
May 26, 2026, 13:40A Century After Its Discovery, VWD Remains Dramatically Underdiagnosed Worldwide – RPTH Journal
-
May 26, 2026, 13:21Isabelle Mahé: Frailty Does Not Mean Less Anticoagulation